Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Potential Harms of rhGH Treatment to Patients With CF: Glucose Control and CFRD (1)
One potential harm of rhGH treatment for patients with CF is an elevated risk of CFRD.
CF directly affects the pancreas, and damage to beta cells results in insulin deficiency. Loss of insulin sensitivity may also play a role in the appearance of this complication.
rhGH regulates glucose utilization and insulin sensitivity, so use of this hormone in patients with CF may influence their risk of developing CFRD.
Keywords: pancreatic | beta cells | insulin | insulin sensitivity | glucose | CFRD | CF-related diabetes | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.